In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warner Chilcott PLC

http://www.wcrx.com/index.jsp

Latest From Warner Chilcott PLC

China Approves Record New Cancer, Orphan Drugs In 2020 But Access Challenges Remain

Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?

Approvals Pink Sheet Perspectives

Deal Watch: Celgene CVR From BMS Buyout Falls Through

Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.

Deals Business Strategies

Rx Drug Promotion: Potential Enforcement Worries

Pitfalls of using third-party hubs for reimbursement assistance, sharing preapproval data with patient groups, and promoting biosimilars with labeling carveouts are among the concerns noted by panelists at FDLI conference.

Advertising, Marketing & Sales Biologics

IPO Update: 58 Drug Developers Raised $12.5bn Through Q3

The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with three additional initial public offerings on 1 October.

Financing Growth
See All

Company Information

  • Other Names / Subsidiaries
    • Galen Holdings PLC
UsernamePublicRestriction

Register